FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.

Share FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Sign up to save your podcasts

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer